Showing 411-420 of 19172 results for "".
Exploring Precision Medicine in the Treatment of Diabetes
https://reachmd.com/programs/diabetes-discourse/exploring-precision-medicine-in-the-treatment-of-diabetes/14210/What would precision medicine in treating diabetes look like when applied to clinical practice? Find out more.Injectable Medication as an Alternative Treatment for Diabetic Eye Disease
https://reachmd.com/programs/the-jama-report/injectable-medication-alternative-treatment-diabetic-eye-disease/7767/[Read the Article] Proliferative diabetic retinopathy (PDR) is a leading cause of vision loss in patients with diabetes, resulting in up to 24,000 cases of blindness each year in the United States. Laser therapy has been the most common treatment used to help reduce severe vision loss, but the proceThe Benefits of Physical Therapy for Patients With Diabetes
https://reachmd.com/programs/diabetes-discourse/the-benefits-of-physical-therapy-for-patients-with-diabetes/5677/It is well established that exercise is a critical component in the management of diabetes, but many diabetes patients struggle with exercise. Physical therapists are the "exercise experts" in the guidance of patients' overall care. What are the benefits of physical therapy for patients living withTreatment Modalities for Diabetic Retinopathy
https://reachmd.com/programs/revealing-retina/treatment-modalities-for-diabetic-retinopathy/5626/The standard treatment for proliferative and non-proliferative diabetic retinopathy is laser photocoagulation, but novel methods, including injectable steroids or anti-vascular endothelial growth factor, are also showing promise. What tests can help opthamologists determine the area of leakage in thKeys to Reversing Pediatric Non-Alcoholic Fatty Liver Disease
https://reachmd.com/programs/lipid-luminations/keys-to-reversing-pediatric-non-alcoholic-fatty-liver-disease/4296/Non-alcoholic fatty liver disease (NAFLD) is increasingly common among our young obese patients, a population for which cardiovascular disease and diabetes is a significant concern. Can measured levels of liver fat serve to help us gauge future risk for metabolic consequences in children? Host Dr. LEffects of aldose reductase inhibitor on exercise capacity in diabetic cardiomyopathy
https://reachmd.com/programs/acc-action-center/effects-of-aldose-reductase-inhibitor-on-exercise-capacity-in-diabetic-cardiomyopathy/24360/ACC.24 - Can treatment with the selective aldose reductase inhibitor AT-001 prevent deterioration of exercise capacity and the onset of HF in patients with diabetic cardiomyopathy? James Januzzi shares the results of ARISE-HF.Physiogenomics and Diabetes
https://reachmd.com/programs/clinicians-roundtable/physiogenomics-and-diabetes/1911/Is the risk of the glitazones worth the benefit? What if you could predict which patients were susceptible? Dr. Ruaño discusses with host Dr. Leslie Lundt how diabetes patients may benefit from the rapidly growing field of physiogenomics.When & How to Screen Patients for Diabetes
https://reachmd.com/programs/diabetes-discourse/when-how-to-screen-patients-for-diabetes/12380/How early should we start screening for diabetes, and what tools are available to us? Dr. John Buse answers this FAQ in honor of Diabetes Alert Day.Diabetes in Pregnancy--The Coming Storm
https://reachmd.com/programs/clinicians-roundtable/diabetes-in-pregnancy-the-coming-storm/1792/A storm is coming, but few have heard the forecast. The obesity epidemic in the United States in all age groups will lead to a huge increase in diabetes during pregnancy. Our guest today is Doctor Thomas Moore. He is Professor and Chairman of the Department of Reproductive Medicine, UniversitA Wake-Up Call to Diabetes: Spreading Awareness of Its Seriousness
https://reachmd.com/programs/diabetes-discourse/a-wake-up-call-to-diabetes-spreading-awareness-of-its-seriousness/12378/It can be tempting for patients to undermine the seriousness of diabetes, but Dr. John Buse explains why we need to set the record straight.